HUP0000356A2 - Hibás vírusgenomokon alapuló rekombináns vektorok és alkalmazásuk vakcinák kialakítására - Google Patents
Hibás vírusgenomokon alapuló rekombináns vektorok és alkalmazásuk vakcinák kialakításáraInfo
- Publication number
- HUP0000356A2 HUP0000356A2 HU0000356A HUP0000356A HUP0000356A2 HU P0000356 A2 HUP0000356 A2 HU P0000356A2 HU 0000356 A HU0000356 A HU 0000356A HU P0000356 A HUP0000356 A HU P0000356A HU P0000356 A2 HUP0000356 A2 HU P0000356A2
- Authority
- HU
- Hungary
- Prior art keywords
- defective
- genome
- viral genome
- defective viral
- vaccines
- Prior art date
Links
- 230000002950 deficient Effects 0.000 title abstract 5
- 230000003612 virological effect Effects 0.000 title abstract 5
- 239000013598 vector Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 2
- 230000010076 replication Effects 0.000 abstract 2
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 241000282326 Felis catus Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 101710172711 Structural protein Proteins 0.000 abstract 1
- 241000282887 Suidae Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000012678 infectious agent Substances 0.000 abstract 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 abstract 1
- 229940031348 multivalent vaccine Drugs 0.000 abstract 1
- 230000001566 pro-viral effect Effects 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
- A61K39/225—Porcine transmissible gastroenteritis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20041—Use of virus, viral particle or viral elements as a vector
- C12N2770/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20061—Methods of inactivation or attenuation
- C12N2770/20064—Methods of inactivation or attenuation by serial passage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A találmány tárgyát legalább egy, szisztémás és szekréciósimműnválaszők kiváltására alkalmas antigént expresszáló hibásrekőmbináns vírűsgenőmőt tartalmazó vektőrők képezik. A hibásvírűsgenőm tartalmazza a 3'- és 5' -végein vírűs-replikáz felismerésiszignálőkkal rendelkező, belső deléciókat hőrdőzó elődvírűsgenőmőt, ésa hibás vírűsgenőm replikáció szempőntjából helper vírűstól függ. Atalálmány szerinti a vektőrők alkalmasak egy, (a) a találmány szerintiexpressziós vektőrt és (b) egy helper vírűst tartalmazó rekőmbinánsrendszer kialakítására, amely biztősítja a hibás genőm replikációjáhőzés kapszidba zárásáhőz szükséges fűnkciőnális és strűktúrfehérjéket. Atalálmány szerinti megőldás alkalmas mőnő- és pőlivalens vakcinákgyártására különböző állatfajők, különösen sertések, kűtyák és macskákfertőző ágensei ellen. ŕ
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES9600620A ES2109189B1 (es) | 1996-03-14 | 1996-03-14 | Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas. |
PCT/ES1997/000059 WO1997034008A1 (es) | 1996-03-14 | 1997-03-12 | Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0000356A2 true HUP0000356A2 (hu) | 2000-06-28 |
HUP0000356A3 HUP0000356A3 (en) | 2001-09-28 |
Family
ID=8294176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0000356A HUP0000356A3 (en) | 1996-03-14 | 1997-03-12 | Vectors based on recombinant defective viral genomes,and their use in the formulation of vaccines |
Country Status (13)
Country | Link |
---|---|
US (3) | US7041300B1 (hu) |
EP (2) | EP1741789A1 (hu) |
JP (1) | JP3769300B2 (hu) |
KR (1) | KR100360327B1 (hu) |
CN (1) | CN1318596C (hu) |
AU (1) | AU729044B2 (hu) |
BR (1) | BR9708061A (hu) |
CA (1) | CA2248978A1 (hu) |
ES (1) | ES2109189B1 (hu) |
HU (1) | HUP0000356A3 (hu) |
PL (1) | PL188546B1 (hu) |
RU (1) | RU2199584C2 (hu) |
WO (1) | WO1997034008A1 (hu) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000077043A2 (fr) * | 1999-06-10 | 2000-12-21 | Merial | Vaccins adn pour animaux de compagnie et de sport |
ES2170622B1 (es) * | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
US6764685B1 (en) | 2000-03-21 | 2004-07-20 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines |
US8715922B2 (en) | 2001-01-19 | 2014-05-06 | ViroNovative | Virus causing respiratory tract illness in susceptible mammals |
US7449324B2 (en) | 2002-02-21 | 2008-11-11 | Vironovative Bv | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences |
PL213926B1 (pl) | 2001-01-19 | 2013-05-31 | Vironovative Bv | Wyizolowany ssaczy metapneumowirus o ujemnej pojedynczej nici RNA (MPV), kompozycja immunogenna, wyizolowane kwasy nukleinowe, sposoby wykrywania ssaczego metapneumowirusa, wektor, komórka gospodarza, wyizolowane bialko, przeciwcialo, sposób wirologicznego diagnozowania infekcji MPV, sposób serologicznego diagnozowania infekcji MPV, kompozycja farmaceutyczna, zestaw diagnostyczny oraz zastosowanie kompozycji farmaceutycznej |
ES2208051B1 (es) * | 2002-01-24 | 2005-08-16 | Consejo Sup. Investig. Cientificas | Secuencia de acido nucleico que comprende la señal de encapsidacion del rna de un coronavirus del grupo 1 y sus aplicaciones. |
WO2004096993A2 (en) | 2003-04-25 | 2004-11-11 | Medimmune Vaccines, Inc. | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus |
EP1650308A1 (en) * | 2004-09-03 | 2006-04-26 | Consejo Superior De Investigaciones Cientificas | Nucleic acid sequences encoding proteins capable of associating into a virus-like particle |
WO2006024542A1 (en) * | 2004-09-03 | 2006-03-09 | Consejo Superior De Investigaciones Cientificas | Nucleic acid sequences encoding proteins capable of associating into a virus-like particle |
US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
WO2006138435A2 (en) * | 2005-06-16 | 2006-12-28 | Mount Sinai School Of Medicine | Methods for enhancing immune responses |
EP1792996A1 (en) * | 2005-12-01 | 2007-06-06 | Consejo Superior de Investigaciones Cientificas | Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV) |
US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
BRPI0800485B8 (pt) * | 2008-01-17 | 2021-05-25 | Univ Minas Gerais | vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose |
EP2353610A4 (en) * | 2008-11-19 | 2013-12-11 | Avi Mex S A De C V Lab | RECOMBINANT INACTIVATED VIRUS VECTOR VACCINE |
CN104262488B (zh) * | 2014-09-24 | 2017-07-28 | 普莱柯生物工程股份有限公司 | 一种融合蛋白及其疫苗组合物的制备与应用 |
EP4136218A1 (en) * | 2020-04-12 | 2023-02-22 | Novoscope IP Limited | Particles, dna & rna |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166057A (en) * | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
EP0647655B1 (en) * | 1993-01-23 | 1998-12-23 | Inmunologia Y Genetica Aplicada, S.A. | Synthetic peptides and vaccines against parvovirus |
-
1996
- 1996-03-14 ES ES9600620A patent/ES2109189B1/es not_active Expired - Fee Related
-
1997
- 1997-03-12 CA CA 2248978 patent/CA2248978A1/en not_active Abandoned
- 1997-03-12 KR KR10-1998-0707192A patent/KR100360327B1/ko not_active IP Right Cessation
- 1997-03-12 HU HU0000356A patent/HUP0000356A3/hu unknown
- 1997-03-12 BR BR9708061A patent/BR9708061A/pt not_active Application Discontinuation
- 1997-03-12 WO PCT/ES1997/000059 patent/WO1997034008A1/es active IP Right Grant
- 1997-03-12 JP JP53230497A patent/JP3769300B2/ja not_active Expired - Fee Related
- 1997-03-12 EP EP20060013756 patent/EP1741789A1/en not_active Withdrawn
- 1997-03-12 PL PL97328791A patent/PL188546B1/pl not_active IP Right Cessation
- 1997-03-12 US US09/155,003 patent/US7041300B1/en not_active Expired - Fee Related
- 1997-03-12 RU RU98118555A patent/RU2199584C2/ru not_active IP Right Cessation
- 1997-03-12 AU AU19277/97A patent/AU729044B2/en not_active Ceased
- 1997-03-12 CN CNB971946140A patent/CN1318596C/zh not_active Expired - Fee Related
- 1997-03-12 EP EP19970907111 patent/EP1008652A1/en not_active Withdrawn
-
2003
- 2003-05-23 US US10/444,059 patent/US20040052775A1/en not_active Abandoned
-
2006
- 2006-08-14 US US11/503,214 patent/US20070048862A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2248978A1 (en) | 1997-09-18 |
JP2000513565A (ja) | 2000-10-17 |
CN1318596C (zh) | 2007-05-30 |
WO1997034008A1 (es) | 1997-09-18 |
BR9708061A (pt) | 2000-01-04 |
PL188546B1 (pl) | 2005-02-28 |
JP3769300B2 (ja) | 2006-04-19 |
CN1218513A (zh) | 1999-06-02 |
KR100360327B1 (ko) | 2003-03-28 |
ES2109189B1 (es) | 1998-05-16 |
US20040052775A1 (en) | 2004-03-18 |
US20070048862A1 (en) | 2007-03-01 |
EP1741789A1 (en) | 2007-01-10 |
US7041300B1 (en) | 2006-05-09 |
PL328791A1 (en) | 1999-02-15 |
AU729044B2 (en) | 2001-01-25 |
ES2109189A1 (es) | 1998-01-01 |
AU1927797A (en) | 1997-10-01 |
KR19990087724A (ko) | 1999-12-27 |
EP1008652A1 (en) | 2000-06-14 |
RU2199584C2 (ru) | 2003-02-27 |
HUP0000356A3 (en) | 2001-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0000356A2 (hu) | Hibás vírusgenomokon alapuló rekombináns vektorok és alkalmazásuk vakcinák kialakítására | |
DE3677494D1 (de) | Virus-impfstoff. | |
DE69632235D1 (de) | Newcastle-Krankheitsvirus-Kombinationsimpfstoff | |
ATE144552T1 (de) | Rekombinantes geflügelpockenvirus | |
DE3888086D1 (de) | Rekombinantes Geflügelpockenvirus, Expressionsvektoren für heterologische Proteine und davon derivierte Geflügelvakzine. | |
DK672789D0 (da) | Nukleinsyresekvens samt rekombinant vaertscelle transformeret med samme | |
PT652287E (pt) | Vectores de poxvirus e sua utilizacao contra doenca pelo virus da peritonite infecciosa felina | |
SE9202968D0 (sv) | New peptides, diagnostic antigens, use thereof, vaccines and medicaments | |
DK457687D0 (da) | Antigenisk aktive proteiner og peptider, og vacciner mod virus for felin peritonitis (fipv) med indhold af saadanne proteiner eller peptider | |
NO885090L (no) | Polypeptider. | |
FR2620030B1 (fr) | Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus | |
FI953371A (fi) | TBE-virusinfektiota vastaan tähtäävään immunisointiin tarkoitetut parannetut rokotteet sekä menetelmä niiden valmistamiseksi | |
DK257887A (da) | Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden | |
ATE102252T1 (de) | Rekombinantes gefluegelpockenvirus, expressionsvektoren fuer heterologische proteine und davon derivierte gefluegelvakzine. | |
NO902491D0 (no) | Proteiner, vaksiner og nukleinsyrer. | |
KR980000469A (ko) | Hbv 항원단백질을 발현하는 키메라 폴리오바이러스 백신벡터를 이용한 면역화 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |